Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

This study has been completed.
Information provided by:
CASI Pharmaceuticals, Inc. Identifier:
First received: March 6, 2007
Last updated: August 3, 2011
Last verified: August 2011